^
    Back
    Association details:
    Biomarker:DLL3 expression
    Cancer:Merkel Cell Carcinoma
    Drug:Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    The Oncologist
    Title:

    Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma

    Published date:
    05/14/2020
    Excerpt:
    A 67‐year‐old patient with metastatic Merkel cell carcinoma...was enrolled into an open‐label study of Rova‐T in subjects with DLL3‐expressing advanced solid tumors...This patient received three doses of Rova‐T at 0.2 mg/kg. This patient's target lesions decreased 57% after the first two cycles of Rova‐T, consistent with radiographic partial response...
    DOI:
    10.1634/theoncologist.2019-0877